Drug Profile
Desidustat - Zydus Cadila
Alternative Names: Oxemia; ZYAN-1; ZYAN-1-1001Latest Information Update: 03 Jun 2022
Price :
$50
*
At a glance
- Originator Zydus Cadila
- Developer China Medical System; Zydus Cadila
- Class Acetic acids; Amides; Antianaemics; Cyclopropanes; Quinolines; Small molecules
- Mechanism of Action Hypoxia-inducible factor-proline dioxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Anaemia
- Phase II COVID 2019 infections
- Phase I Chemotherapy-induced anaemia